You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1

 

Online download statistics by month:

Online download statistics by month: November 2023 to November 2024

AbstractFullPdf
Nov 2023394023
Dec 202353011
Jan 202410002
Feb 20244403
Mar 20249407
Apr 20247004
May 20247606
Jun 20244201
Jul 20246209
Aug 20245405
Sep 20248808
Oct 202452014
Nov 202466012
Total11950105